These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23686805)

  • 1. Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors.
    Han X; Zhao J; Ji Y; Xu X; Lou W
    Tumour Biol; 2013 Oct; 34(5):2881-9. PubMed ID: 23686805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.
    Han X; Ji Y; Zhao J; Xu X; Lou W
    Tumour Biol; 2013 Oct; 34(5):2871-9. PubMed ID: 23686804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors.
    Cherenfant J; Talamonti MS; Hall CR; Thurow TA; Gage MK; Stocker SJ; Lapin B; Wang E; Silverstein JC; Mangold K; Odeleye M; Kaul KL; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA
    Surgery; 2014 Dec; 156(6):1504-10; discussion 1510-1. PubMed ID: 25456943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.
    Zhang L; Smyrk TC; Oliveira AM; Lohse CM; Zhang S; Johnson MR; Lloyd RV
    Am J Surg Pathol; 2009 Oct; 33(10):1562-9. PubMed ID: 19574886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm.
    Zhang L; Lohse CM; Dao LN; Smyrk TC
    Hum Pathol; 2011 Mar; 42(3):324-31. PubMed ID: 21190722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
    Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center.
    Han X; Xu X; Jin D; Wang D; Ji Y; Lou W
    Pancreas; 2014 May; 43(4):526-31. PubMed ID: 24658317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
    Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
    Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.
    Zhou B; Fang B; Yan S; Wang W
    Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms.
    Simtniece Z; Vanags A; Strumfa I; Sperga M; Vasko E; Prieditis P; Trapencieris P; Gardovskis J
    Pol J Pathol; 2015 Jun; 66(2):176-94. PubMed ID: 26247532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification.
    Brunner SM; Weber F; Werner JM; Agha A; Farkas SA; Schlitt HJ; Hornung M
    BMC Surg; 2015 Apr; 15():49. PubMed ID: 25928025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors.
    Yang B; Chen HY; Zhang XY; Pan Y; Lu YF; Yu RS
    Eur J Radiol; 2020 Mar; 124():108847. PubMed ID: 31991300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
    Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
    Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production.
    Tsutsumi K; Ohtsuka T; Mori Y; Fujino M; Yasui T; Aishima S; Takahata S; Nakamura M; Ito T; Tanaka M
    J Gastroenterol; 2012 Jun; 47(6):678-85. PubMed ID: 22350698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
    Mirkin KA; Hollenbeak CS; Wong J
    J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Prognostic Significances of Cytokeratin 19 and KIT Expression in Surgically Resectable Pancreatic Neuroendocrine Tumors.
    Son EM; Kim JY; An S; Song KB; Kim SC; Yu E; Hong SM
    J Pathol Transl Med; 2015 Jan; 49(1):30-6. PubMed ID: 25812655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
    Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
    Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.